TR201903978T4 - L-ornitin fenil asetat yapım yöntemleri. - Google Patents

L-ornitin fenil asetat yapım yöntemleri. Download PDF

Info

Publication number
TR201903978T4
TR201903978T4 TR2019/03978T TR201903978T TR201903978T4 TR 201903978 T4 TR201903978 T4 TR 201903978T4 TR 2019/03978 T TR2019/03978 T TR 2019/03978T TR 201903978 T TR201903978 T TR 201903978T TR 201903978 T4 TR201903978 T4 TR 201903978T4
Authority
TR
Turkey
Prior art keywords
phenyl acetate
ornithine phenyl
making methods
ornithine
acetate making
Prior art date
Application number
TR2019/03978T
Other languages
English (en)
Inventor
H Anderson Keith
Behling Jim
Henderson Dougan Christine
William Watt Stephen
Manini Peter
Figini Attilia
Original Assignee
Ocera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocera Therapeutics Inc filed Critical Ocera Therapeutics Inc
Publication of TR201903978T4 publication Critical patent/TR201903978T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Buluş, L-ornitin fenil asetat tuzu yapımı için bir proses olup, bir fenil asetik asit ve bir çözücü olarak bir bazın karıştırılması yoluyla fenil asetat tuzunun bir çözeltisinin hazırlanması, fenil asetat tuzunun bir çözeltisi ile L-ornitin benzoat'ın birbirine karıştırılması ve L-ornitin fenil asetat içeren bir bileşimin izole edilmesi işlem adımlarını içermesi ile ilgilidir.
TR2019/03978T 2010-10-06 2011-10-05 L-ornitin fenil asetat yapım yöntemleri. TR201903978T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39058510P 2010-10-06 2010-10-06

Publications (1)

Publication Number Publication Date
TR201903978T4 true TR201903978T4 (tr) 2019-04-22

Family

ID=45928120

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/03978T TR201903978T4 (tr) 2010-10-06 2011-10-05 L-ornitin fenil asetat yapım yöntemleri.

Country Status (16)

Country Link
US (2) US8946473B2 (tr)
EP (1) EP2625162B1 (tr)
JP (1) JP6087284B2 (tr)
KR (1) KR101888215B1 (tr)
CN (1) CN103502203B (tr)
AU (1) AU2011312042B2 (tr)
BR (1) BR112013008054B1 (tr)
CA (1) CA2813563C (tr)
EA (1) EA028395B1 (tr)
ES (1) ES2720148T3 (tr)
IL (1) IL225512A (tr)
MX (1) MX360062B (tr)
NZ (1) NZ609191A (tr)
SG (1) SG189231A1 (tr)
TR (1) TR201903978T4 (tr)
WO (1) WO2012048043A1 (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2319581T1 (sl) 2004-11-26 2015-10-30 Ucl Business Plc Pripravki, ki obsegajo ornitin in fenilacetat ali fenilbutirat za zdravljenje hepatične encefalopatije
EP3686183B1 (en) 2009-04-03 2022-08-03 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
AU2010258888B2 (en) 2009-06-08 2014-08-07 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
US8946473B2 (en) * 2010-10-06 2015-02-03 Ocera Therapeutics, Inc. Methods of making L-ornithine phenyl acetate
BR112017010761B1 (pt) 2014-11-24 2022-10-18 Ucl Business Plc Tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia
ES2944311T3 (es) * 2015-04-20 2023-06-20 Ocera Therapeutics Inc Formulaciones de fenilacetato de L-ornitina
WO2017031131A1 (en) * 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
AU2016353350B2 (en) * 2015-11-13 2021-09-23 Ocera Therapeutics, Inc. Formulation of L-ornithine phenylacetate
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
EP3621947A4 (en) * 2017-05-11 2021-03-10 Ocera Therapeutics, Inc. L-ORNITHINE PHENYLACETATE MANUFACTURING PROCESSES
CA3070856A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. Amino acid for the treatment of liver disease
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
NL302572A (tr) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
US4100293A (en) 1974-04-15 1978-07-11 The Johns Hopkins University Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids
US3950529A (en) 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4228099A (en) 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4352814A (en) 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
DE4020980C1 (tr) 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
US5591613A (en) 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
JP3127484B2 (ja) 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
US5767086A (en) 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
NZ255541A (en) 1992-09-09 1996-05-28 Fisons Plc Blister package for medicament-containing capsules with an aperture for dispensing the medicament; the package base has a sealing means to seal the capsule aperture
US5571783A (en) 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
JP3273578B2 (ja) * 1993-09-21 2002-04-08 第一化学薬品株式会社 オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
US5840891A (en) 1994-07-28 1998-11-24 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
AU2251897A (en) 1996-02-13 1997-09-02 Trustees Of The University Of Pennsylvania, The Method of treating liver disorders
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
WO2000071151A1 (fr) 1999-05-21 2000-11-30 Takeda Chemical Industries, Ltd. Regulateurs des fonctions hepatiques
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
EP1374863B1 (en) 2001-03-15 2009-09-02 Riken Amino acid compositions for ameliorating liver failure
US6503530B1 (en) 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
CN1383815A (zh) 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
WO2004019928A1 (ja) 2002-08-30 2004-03-11 Ajinomoto Co., Inc. 肝疾患治療剤
US20050059150A1 (en) 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
MXPA03009902A (es) 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
CN101010087B (zh) 2004-05-06 2012-06-27 奥斯泰奥洛吉斯公司 用于制备金属有机盐的高收率和快速的合成方法
CA2582255A1 (en) 2004-08-30 2006-08-08 Lunamed, Inc. 4-phenylbutyric acid controlled-release formulations for therapeutic use
SI2319581T1 (sl) 2004-11-26 2015-10-30 Ucl Business Plc Pripravki, ki obsegajo ornitin in fenilacetat ali fenilbutirat za zdravljenje hepatične encefalopatije
ME01879B (me) 2005-11-17 2014-12-20 Stabilna formulacija amorfnih perindopril soli, postupak njihove pripreme, posebno industrijske proizvodnje i njihova upotreba u terapiji hipertenzije
CN201421432Y (zh) * 2009-02-20 2010-03-10 山东师范大学 一种相干衍射成像处理装置
EP3686183B1 (en) 2009-04-03 2022-08-03 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
AU2010258888B2 (en) 2009-06-08 2014-08-07 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
US8946473B2 (en) 2010-10-06 2015-02-03 Ocera Therapeutics, Inc. Methods of making L-ornithine phenyl acetate

Also Published As

Publication number Publication date
MX360062B (es) 2018-10-22
EP2625162B1 (en) 2019-03-13
EP2625162A1 (en) 2013-08-14
US20130211135A1 (en) 2013-08-15
CN103502203A (zh) 2014-01-08
CN103502203B (zh) 2016-09-07
JP6087284B2 (ja) 2017-03-01
US20150133684A1 (en) 2015-05-14
ES2720148T3 (es) 2019-07-18
CA2813563C (en) 2019-02-26
IL225512A (en) 2017-12-31
US9260379B2 (en) 2016-02-16
KR101888215B1 (ko) 2018-09-20
BR112013008054B1 (pt) 2019-04-09
KR20140053807A (ko) 2014-05-08
MX2013003764A (es) 2013-05-20
IL225512A0 (en) 2013-06-27
CA2813563A1 (en) 2012-04-12
AU2011312042A1 (en) 2013-05-02
EA028395B1 (ru) 2017-11-30
JP2013542935A (ja) 2013-11-28
EP2625162A4 (en) 2014-06-25
US8946473B2 (en) 2015-02-03
AU2011312042B2 (en) 2015-08-20
SG189231A1 (en) 2013-05-31
BR112013008054A2 (pt) 2016-06-14
EA201390403A1 (ru) 2013-09-30
NZ609191A (en) 2015-06-26
WO2012048043A1 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
TR201903978T4 (tr) L-ornitin fenil asetat yapım yöntemleri.
MY156938A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
BR112012017831A8 (pt) micro-organismos produtores de ácido eicosapentaenoico, composições de ácido graxo e métodos de fabricação e uso dos mesmos
MA33939B1 (fr) 5-alcynyl-pyrimidines
WO2014097099A3 (en) Glycoconjugation process
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
ECSP13012958A (es) Inhibidores de benzodioxano de la producción de leucotrieno.
EA201391313A1 (ru) C4-монометилтритерпеноидные производные и способы их применения
NZ705213A (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
EA201100666A1 (ru) Тиоамидные соединения, способ их получения и способ их применения
MX350211B (es) Proceso para la preparacion del etil-ester del acido n- (4-ciclohexil-3-trifluoro-metil-benciloxi) -acetimidico.
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
EA201490846A1 (ru) Новые производные арилхинолина
AU2009310099A8 (en) Agricultural compositions
WO2013072768A3 (en) Synthetic derivatives of mpl and uses thereof
MA33948B1 (fr) Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques.
EA201300443A1 (ru) Способ получения дигидроптеридинонов и их промежуточных продуктов
UY33548A (es) Formula nutricional predigerida
IN2014MN00850A (tr)
MX2012007870A (es) Derivados de acido carboxilico que comprende un anillo de oxazolopirimidina 2, 5, 7-sustituido.
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
IN2015DN00085A (tr)
MX2013013262A (es) Derivados de ciclododecadienona como ingredientes de perfumado.
TN2014000329A1 (en) Method for preparing compound by novel michael addition reaction using water or various acids as additive